Rhizen Pharmaceuticals S.A.;TG Therapeutics Inc.;Laboratoire Français du Fractionnement et des Biotechnologies
发明人:
Vakkalanka, Swaroop K.V.S,Weiss, Michael,Miskin, Hari,Sportelli, Peter
申请号：
DK16185090
公开号：
DK3150256T3
申请日:
2013.11.01
申请国别(地区):
DK
年份:
2020
代理人:
摘要：
Highly effective combinations of a compound of formula A (a PI3K´ selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K´ and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.
